Reuters logo
BRIEF-Spero Therapeutics initiates clinical program for SPR994
October 20, 2017 / 12:21 PM / a month ago

BRIEF-Spero Therapeutics initiates clinical program for SPR994

Oct 20 (Reuters) - Spero Therapeutics Inc

* Spero Therapeutics initiates clinical program for oral carbapenem SPR994

* Spero Therapeutics - plans for rapid development approach with SPR994 that supports initiation of single pivotal phase 3 trial in second half of 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below